baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Foghorn Therapeutics/ US3441741077 /

2024-05-16 8:57:08 PM	Chg. +0.40	Volume	Bid-	Ask-	High	Low
5.77USD	+7.45%	381 Turnover: 2,144.99	-Bid Size: -	-Ask Size: -	5.80	5.41

GlobeNewswire 05-06 Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update

GlobeNewswire 04-16 Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Fi...

GlobeNewswire 04-09 Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibit...

GlobeNewswire 04-05 Foghorn Therapeutics to Participate in Needham’s 23rd Annual Virtual Healthcare Conference

GlobeNewswire 03-26 Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Con...

GlobeNewswire 03-07 Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook

GlobeNewswire 03-05 Foghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advance...

GlobeNewswire 02-28 Foghorn Therapeutics to Participate in Cowen’s 44th Annual Health Care Conference

GlobeNewswire 02-15 OnKure Announces the Appointment of Samuel Agresta, M.D., as Chief Medical Officer

GlobeNewswire 02-08 Foghorn Provides Pipeline Update on FHD-909 BRM Selective Inhibitor

GlobeNewswire 01-08 Foghorn Therapeutics Highlights Clinical Program Updates and Research Progress and Provides Strategi...

GlobeNewswire 01-05 Prime Medicine Appoints Allan Reine, M.D., as Chief Financial Officer

GlobeNewswire 01-03 Foghorn Therapeutics Announces CFO Departure

GlobeNewswire 2023-12-01 Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286, a Novel BRG1/BRM Inhibit...

GlobeNewswire 2023-11-02 Foghorn Therapeutics Provides Third Quarter 2023 Financial and Corporate Update

GlobeNewswire 2023-10-24 Foghorn Therapeutics to Present at Upcoming Conferences Including New Preclinical Data from EP300 an...

GlobeNewswire 2023-10-13 Foghorn Therapeutics Announces Clinical Data From Phase 1 Study of FHD-286 in Metastatic Uveal Melan...

GlobeNewswire 2023-10-04 Foghorn Therapeutics to Present Clinical and Pre-Clinical Data from Multiple Programs Across Its Div...

GlobeNewswire 2023-09-05 Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences

GlobeNewswire 2023-08-31 Foghorn Therapeutics Announces First Patient Dosed in Phase 1 Combination Study of FHD-286 for Relap...

GlobeNewswire 2022-03-11 Foghorn Therapeutics to Participate at the 2022 Guggenheim Targeted Protein Degradation Day

GlobeNewswire 2022-03-10 Foghorn Therapeutics Provides Full Year 2021 Corporate Update and 2022 Outlook

GlobeNewswire 2022-02-28 Foghorn Therapeutics to Participate at the Cowen’s 42nd Annual Health Care Conference

GlobeNewswire 2022-01-10 Foghorn Therapeutics Announces Chief Scientific Officer Succession

GlobeNewswire 2022-01-07 Foghorn Therapeutics to Participate at the H.C. Wainwright BioConnect Conference

Foghorn Therapeutics/ US3441741077 /

If you wish to receive reply to your feedback, please provide your email address.